Cynapsus Wants To Offer Parkinson’s Patients A Friendlier Apomorphine Option
This article was originally published in The Pink Sheet Daily
Executive Summary
Sublingual film formulation of apomorphine, just moving into Phase III, would address “off” episodes with fewer side effect issues and easier administration than the current injectable version.
You may also be interested in...
Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
Personal Care Next Target For UK Competition Authority ‘Greenwashing’ Audit
Manufacturers of UK personal care products watch out, the Competition and Markets Authority is on the look-out for false, exaggerated and/or vague sustainability claims, and may be targeting bigger players to make an example for the rest of the sector. And consumer health might be next. HBW Insight returns to advice from marketing expert Jo Stephenson on how to avoid greenwashing, based on the CMA's own extensive Green Claims Code.
UK MHRA’s New And Increased Medtech Fees In Force in April
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.